Patents by Inventor Fergal Hill
Fergal Hill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9963490Abstract: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.Type: GrantFiled: December 21, 2015Date of Patent: May 8, 2018Assignee: OSIVAX SASInventors: Judith Del Campo Ascarateil, Fergal Hill
-
Publication number: 20160215032Abstract: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.Type: ApplicationFiled: December 21, 2015Publication date: July 28, 2016Inventors: Judith Del Campo Ascarateil, Fergal Hill
-
Patent number: 9388225Abstract: The present application is related to a modified protein comprising a protein having a coiled coil domain and a peptide having the sequence such as shown in SEQ ID NO 1: ZXBBBBZ that is linked to the coiled coil domain wherein: Z is any amino acid or is absent; X is any amino acid; B is an arginine (R) or a lysine (K). Said modified protein is in particular an antigen or a carrier protein, associated to an antigen. This modified protein has an increased affinity for negatively charged polymers such as nucleic acids or heparin, and shows an increased immunogenicity.Type: GrantFiled: December 15, 2014Date of Patent: July 12, 2016Assignee: ImaxioInventors: Judith Del Campo Ascarateil, Imene Turki Hani, Fergal Hill
-
Patent number: 9243047Abstract: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.Type: GrantFiled: December 15, 2014Date of Patent: January 26, 2016Assignee: ImaxioInventors: Judith Del Campo Ascarateil, Fergal Hill
-
Patent number: 9181311Abstract: There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.Type: GrantFiled: October 15, 2010Date of Patent: November 10, 2015Assignees: Isis Innovation Limited, Imaxio SAInventors: Alexandra Jane Spencer, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Fergal Hill
-
Publication number: 20150098958Abstract: The present invention is related to a fusion protein comprising a variant of a nucleoprotein antigen from Influenza strain A, B or C, and a variant of a C4bp oligomerization domain for increasing the cellular immunogenicity of the nucleoprotein antigen from Influenza. The invention is also related to nucleic acids, vectors, fusion proteins and immunogenic compositions, for their use as a vaccine or immunotherapy for the prevention and treatment of influenza disease.Type: ApplicationFiled: December 15, 2014Publication date: April 9, 2015Inventors: Judith DEL CAMPO ASCARATEIL, Fergal HILL
-
Publication number: 20150093406Abstract: The present application is related to a modified protein comprising a protein having a coiled coil domain and a peptide having the sequence such as shown in SEQ ID NO 1: ZXBBBBZ that is linked to the coiled coil domain wherein: Z is any amino acid or is absent; X is any amino acid; B is an arginine (R) or a lysine (K). Said modified protein is in particular an antigen or a carrier protein, associated to an antigen. This modified protein has an increased affinity for negatively charged polymers such as nucleic acids or heparin, and shows an increased immunogenicity.Type: ApplicationFiled: December 15, 2014Publication date: April 2, 2015Inventors: Judith DEL CAMPO ASCARATEIL, Imene TURKI HANI, Fergal HILL
-
Publication number: 20120282290Abstract: There is provided a fusion protein or a polynucleotide sequence encoding said fusion protein that comprises first and second domains, wherein the first domain of the fusion protein comprises an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO: 1, or a fragment thereof comprising at least 20 consecutive amino acids thereof; and wherein the second domain of the fusion protein comprises a mycobacterial antigen or an antigenic fragment thereof. Also provided are corresponding therapeutic uses thereof for the protection of primates against mycobacterial infections.Type: ApplicationFiled: October 15, 2010Publication date: November 8, 2012Applicants: IMAXIO SA, ISIS INNOVATION LIMITEDInventors: Alexandra Jane Spencer, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Fergal Hill
-
Patent number: 8252288Abstract: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.Type: GrantFiled: April 20, 2011Date of Patent: August 28, 2012Assignee: ImaxioInventors: Fergal Hill, Jean-Baptiste Marchand, Laurence Dumon
-
Publication number: 20110195082Abstract: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.Type: ApplicationFiled: April 20, 2011Publication date: August 11, 2011Applicant: IMAXIOInventors: FERGAL HILL, JEAN-BAPTISTE MARCHAND, LAURENCE DUMON
-
Patent number: 7951376Abstract: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.Type: GrantFiled: May 29, 2008Date of Patent: May 31, 2011Assignee: ImaxioInventors: Fergal Hill, Jean-Baptiste Marchand, Laurence Dumon
-
Publication number: 20110064768Abstract: An immunogenic composition comprising a viral vector, said vector comprising a nucleic acid sequence encoding a C4bp domain or variant or fragment thereof and a nucleic acid sequence encoding an antigen of interest.Type: ApplicationFiled: April 10, 2008Publication date: March 17, 2011Inventors: Simon Draper, Adrian Hill, Fergal Hill
-
Publication number: 20090110693Abstract: The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines.Type: ApplicationFiled: May 29, 2008Publication date: April 30, 2009Applicant: ImaxioInventors: Fergal Hill, Jean-Baptiste Marchand, Laurence Dumon
-
Publication number: 20080311106Abstract: The invention provides a product which comprises a C4bp core protein and a monomeric antigen, desirably in the form of a fusion protein. Monomeric antigens include malarial and influenza antigens. The C4bp core protein provides for assembly of multimeric complexes of the monomeric antigen, or mixtures thereof. The complexes are useful as vaccines.Type: ApplicationFiled: August 12, 2004Publication date: December 18, 2008Applicant: IMAXIOInventor: Fergal Hill
-
Publication number: 20070104726Abstract: The present invention provides a product comprising: a first component which is a scaffold; a second component which is an adjuvant, preferably a polypeptide which is a ligand for CD21 or a cell surface molecule on B cells or T cells or follicular dendritic or other antigen presenting cells; and a third component which is an antigen.Type: ApplicationFiled: August 12, 2003Publication date: May 10, 2007Applicant: AVIDIS SAInventors: Pierre Andreoletti, Laurence Dumon, Fergal Hill, Michel Julien, Jean Marchand, Emmanuel Risse
-
Publication number: 20070092933Abstract: The present invention provides a method for obtaining a recombinant fusion protein comprising a scaffold of a C-terminal core protein of C4bp alpha chain, said recombinant fusion protein being capable of forming multimers in soluble form in a prokaryotic host cell, the method including the steps of (i) providing a prokaryotic host cell carrying a nucleicacid encoding said recombinant protein operably linked to a promoter functional in said prokaryotic cell; (ii) culturing the host cell under conditions wherein said recombinant protein is expressed; and (iii) recovering the recombinant protein wherein said protein is recovered in multimeric form without performing a scaffold refolding step.Type: ApplicationFiled: August 12, 2003Publication date: April 26, 2007Applicant: AVIDIS SAInventors: Laurence Garnier, Fergal Hill, Michel Jullen
-
Publication number: 20040091950Abstract: The present invention relates to vectors for use in transposon-based DNA sequencing methods, methods for DNA sequencing using such vectors and a method for preparing improved cloning vectors.Type: ApplicationFiled: March 18, 2003Publication date: May 13, 2004Inventors: Wilhelm Ansorge, Vladimir Benes, Fergal Hill
-
Patent number: 6605611Abstract: Nucleoside analogues or base analogues having structure (I), where X=O or NH or S, Y=N or CHR6 or CR6, W=N or NR6 or CHR6 or CR6 or S, n=1 or 2; each R6 is independently H or O or alkyl or alkenyl or alkoxy or aryl or a reporter moiety; where necessary (i.e. when Y and/or W is N or CR6 where R6 is not O) a double bond is present between Y and W or W and W, and Q is H or a sugar or a sugar analogue or a nucleic acid backbone or backbone analogue.Type: GrantFiled: September 3, 2002Date of Patent: August 12, 2003Assignee: Nycomed Amersham PLCInventors: Adrian Christopher Simmonds, Alan Hamilton, Clifford Smith, David Loakes, Daniel Brown, Fergal Hill, Shiv Kumar, Satyam Nampalli, Mark McDougall
-
Patent number: 6600028Abstract: Nucleoside analogues have structure (2) wherein Q is H or a sugar moiety or sugar analogue or a modified sugar or a nucleic backbone or backbone analogue, W is an alkylene or alkenylene chain of 0-5 carbon atoms, any of which may carry a substituent R8, X is O or N or NR12 or CR10, X′ is O or S or N, provided that when X′ is O or S, then X is C, Y is CH or N, R6 is NH2 or SMe or SO2Me or NHNH2, each of R7 and R8 is independently H or F or alkyl or alkenyl or aryl or acyl or a reporter moiety, R12 is independently H or alkyl or alkenyl or aryl or acyl or a reporter moiety, and R10 is H or ═O or F or alkyl or aryl or a reporter moiety.Type: GrantFiled: February 1, 2000Date of Patent: July 29, 2003Assignee: Amersham Pharmacia Biotech UK LimitedInventors: Daniel Brown, David Loakes, David Williams, Fergal Hill, Shiv Kumar, Satyam Nampalli, Mark McDougall, Alan Hamilton, Clifford Smith, Adrian Christopher Simmonds, William Jonathan Cummins, Patrick Finn
-
Publication number: 20030060431Abstract: Nucleoside analogues or base analogues having structure (1), where X=O or NH or S, Y=N or CHR6 or CR6, W=N or NR6 or CHR6 or CR6 or S, n=1 or 2; each R6 is independently H or O or alkyl or alkenyl or alkoxy or aryl or a reporter moiety; where necessary (i.e. when Y and/or W is N or CR6 where R6 is not O) a double bond is present between Y and W or W and W, and Q is H or a sugar or a sugar analogue or a nucleic acid backbone or backbone analogue.Type: ApplicationFiled: September 3, 2002Publication date: March 27, 2003Applicant: NYCOMED AMERSHAM PLCInventors: Adrian Christopher Simmonds, Alan Hamilton, Clifford Smith, David Loakes, Daniel Brown, Fergal Hill, Shiv Kumar, Satyam Nampalli, Mark McDougall